NEW YORK (Thomson Financial) - Theravance Inc. said late Tuesday it will
offer $150 million of unsecured convertible subordinated notes due 2015 in an
underwritten registered public offering.
Theravance said it plans to grant the underwriters a 30-day option to buy up
to an additional $22.5 million of notes to cover over-allotments.
The South San Francisco, Calif.-based biopharmaceutical company said it
plans use the net proceeds from the offering for general corporate purposes.
Merrill Lynch & Co. and Goldman, Sachs & Co. are acting as joint
book-running managers of the public offering.
The stock closed the regular session at $21.68.
Wanfeng Zhou
wz/kh
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|